STOCK TITAN
  1. Home
  2. News
  3. KNW

Know Labs, Inc. - KNW STOCK NEWS

Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.

Know Labs, Inc. (KNW) is a pioneering company in the medical diagnostics sector, dedicated to the development, marketing, and sales of cutting-edge technologies. The company specializes in utilizing electromagnetic energy to identify, authenticate, and analyze various substances and materials through its proprietary Bio-RFID and ChromaID technologies.

The Bio-RFID technology is revolutionizing the industry by enabling non-invasive glucose monitoring, providing a significant advancement for diabetes management. Similarly, the ChromaID technology uses structured light to capture unique spectral patterns known as ChromAIDs, which can be matched against databases to identify and detect markers invisible to the human eye. These technologies offer potential solutions that were previously only possible with large, lab-based tests.

Know Labs is currently focused on the development of a wearable device designed to measure blood glucose levels without the need for fingersticks or microneedles. This innovative product aims to improve the quality of life for individuals with diabetes by providing a painless and convenient method of monitoring blood sugar levels.

The company has recently achieved significant milestones in its research and development efforts, showcasing its commitment to pushing the boundaries of medical diagnostics. Know Labs is also actively engaged in forging strategic partnerships to enhance its technological capabilities and expand its market reach.

Financially, Know Labs continues to invest in research and development, ensuring it remains at the forefront of medical diagnostic innovation. The company's disruptive technologies hold the promise of making advanced diagnostics more accessible and affordable, thereby transforming the landscape of healthcare.

For the latest updates, news, and developments related to Know Labs, Inc., visit our news section or follow us on our social media channels.

News

Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

Rhea-AI Summary
Know Labs, Inc. (KNW) announces positive interim results from its clinical research study on non-invasive blood glucose monitoring in participants with diabetes. The study demonstrates a Mean Absolute Relative Difference (MARD) of 11.1% using the company's proprietary RF sensor, showing promise for future FDA-cleared continuous glucose monitoring devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
clinical trial
-
News

Know Labs Secures U.S. $12 Million Funding for Company’s Further Execution on Its Clinical Research and Development Initiatives

Rhea-AI Summary
Know Labs, Inc. (KNW) secures a funding agreement for up to $12 million with Lind Global Fund II LP, enabling accelerated development of non-invasive medical diagnostic technology. The investment will support hardware development, expanded data collection, algorithm development, and intellectual property expansion. The company aims to validate its technology in large-scale clinical trials for a non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
clinical trial
-
News

Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor

Rhea-AI Summary
Know Labs, Inc. announces the KnowU, a wearable non-invasive continuous glucose monitor, incorporating a proprietary sensor for FDA submission. The device is smaller, lighter, and includes machine learning capabilities, aiming to revolutionize diabetes management. The KnowU supports accelerated data collection for FDA clinical trials, offering a future solution for accessible and accurate diabetes care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
News

Know Labs, Inc. Reports First Quarter FY2024 Results

Rhea-AI Summary
Know Labs, Inc. (KNW) reported financial results for Q1 FY 2024, showing a 9.8% reduction in net loss, with a net loss of $3.45 million. Earnings Per Share improved by 50% to a loss of $0.04. The company had cash and cash equivalents of $4.82 million as of December 31, 2023. Know Labs aims to raise funds through equity, preferred stock, and convertible debentures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.91%
Tags
earnings
-
News

Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024

Rhea-AI Summary
Know Labs, Inc. (KNW) will host a webcast to review business updates and first quarter results for fiscal year 2024 on February 14, 2024. The company is an emerging developer of non-invasive medical diagnostic technology and is focused on developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences earnings
-
News

Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Rhea-AI Summary
Know Labs, Inc. (KNW) will present updated clinical research results and developments of its non-invasive blood glucose monitor at the International Fair of New Technologies in Diabetes. The company will share updates on the latest developments of its non-invasive blood glucose monitor and present results from its ongoing clinical research, with two abstracts accepted for e-poster presentation in the scientific program. Dr. Virend K. Somers of the Mayo Clinic will present the results from the current clinical research protocol, assessing the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference. Know Labs will also sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) during the conference to discuss non-invasive glucose monitoring innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
News

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results

Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) reported a net loss of $15.29 million dollars in FY2023, compared to a net loss of $20.07 million dollars in FY2022, a reduction in net loss of 23.8%. R&D expenses for FY2023 were $7.73 million dollars, an increase of 43.5% year over year. The company had cash and cash equivalents of $8.02 million dollars, and it expects to raise additional funds through the issuance of equity, preferred stock, and convertible debentures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.33%
Tags
earnings
-
News

Know Labs Expands Medical and Scientific Advisory Board

Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) appoints four new members to its Medical and Scientific Advisory Board. Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan, and Dr. Satish Garg bring extensive clinical diabetes management and FDA expertise to the board. They will support the development and FDA clearance of the company's non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
management
-
News

Know Labs, Inc. to Host Review of Fiscal Year 2023 Results on December 19, 2023

Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT. The company is an emerging developer of non-invasive medical diagnostic technology and is progressing in developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
conferences earnings
News

Know Labs Expands Board of Directors

Rhea-AI Summary
KNW: Know Labs, Inc. Appoints Three New Directors with Deep Sector Expertise. The company has named John Cronin, Larry Ellingson, and Tim Londergan to its Board of Directors. The new appointees bring extensive sector-relevant experience and deep knowledge of the science and marketplace focused on Know Labs, expanding the board to seven members. John Cronin, the founder and CEO of ipCapital Group, Inc., has played a pivotal role in increasing Know Labs' patent portfolio and global leadership in non-invasive blood glucose monitoring. Larry Ellingson, with 30 years at Eli Lilly, has been instrumental in shaping Know Labs' strategy and global relationships. Tim Londergan, founder and CEO of Tangibly, Inc., brings expertise in trade secret management and enhancing IP portfolios.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management

FAQ

What is the current stock price of Know Labs (KNW)?

The current stock price of Know Labs (KNW) is $0.2452 as of November 22, 2024.

What is the market cap of Know Labs (KNW)?

The market cap of Know Labs (KNW) is approximately 27.5M.

What does Know Labs, Inc. specialize in?

Know Labs, Inc. specializes in the development, marketing, and sales of technologies that use electromagnetic energy to identify and authenticate substances and materials.

What is Bio-RFID technology?

Bio-RFID technology is a non-invasive method developed by Know Labs to measure blood glucose levels without fingersticks or microneedles.

What is ChromaID technology?

ChromaID technology uses structured light to capture unique spectral patterns, known as ChromAIDs, which can identify and detect markers invisible to the human eye.

What is the latest product being developed by Know Labs?

Know Labs is currently developing a wearable device that measures blood glucose levels non-invasively.

What are ChromAIDs?

ChromAIDs are unique spectral patterns captured by ChromaID technology, used to identify and detect various markers.

How does Know Labs' technology differ from traditional diagnostic methods?

Know Labs' technologies offer non-invasive, portable, and cost-effective diagnostic solutions that were traditionally only possible with large, lab-based equipment.

What are the recent achievements of Know Labs?

Know Labs has achieved significant milestones in research and development, advancing its Bio-RFID and ChromaID technologies and working on a non-invasive glucose monitoring device.

How does Know Labs contribute to diabetes management?

Know Labs is developing a wearable device for non-invasive glucose monitoring, which aims to provide a painless and convenient method for individuals to manage their blood sugar levels.

Who can benefit from Know Labs' technologies?

Individuals with diabetes, medical professionals, and various industries requiring substance identification and authentication can benefit from Know Labs' innovative technologies.

Where can I find the latest news about Know Labs, Inc.?

You can find the latest updates and news about Know Labs, Inc. on their news section on their website or follow them on social media channels.

Stock KNW logo
Know Labs, Inc.

NYSE:KNW

KNW Rankings

#5168 Ranked by Market Cap
N/A Ranked by Dividends

KNW Stock Data

27.46M
79.96M
26.05%
4.83%
1.2%
Scientific & Technical Instruments
Measuring & Controlling Devices, Nec
Link
United States of America
SEATTLE